Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.

Rationale: Valproic Acid is a commonly used psychiatric drug primarily used as a mood stabilizer. Mild hyperammonemia is a Valproic Acid common adverse effect. This report presents an example of treated hyperammonemia on Valproic acid therapy managed with L-carnitine administration in BD patients characterized by sudden vulnerability.

Topiramate for binge eating disorder.

Topiramate is a new anti convulsant agent that acts on the voltage-activated sodium channels and on the glutamate and GABA receptors; it is furthermore able to reduce hunger and therefore contributes to loss of weight. The authors report the case of a patient suffering from binge eating disorder, who was unresponsive to several therapeutic plans but was successfully treated with topiramate.

[Psychotic disorders induced by interferon alfa].

The treatment with interferon-alpha is contraindicated in patients with major depression (National Institutes of Health), but a considerable number of neuropsychiatric side effects is associated with it: personality changes, impaired cognitive, mania, psychosis. In the literature limited reports of interferon-alpha-induced psychotic disorder exist. Authors report on a 46-year-old man diagnosed with alcohol induced psychotic disorder, who had been started to a treatment with Pegylated Interferon alfa-2b [Peg-Intron] and Ribavirin owing to a previous HCV-induced chronic hepatitis associated with a significant change in liver enzymes.